BeiGene grants Merck ex-Chinese rights to BeiGene-290

BeiGene Co. Ltd. (Beijing, China) granted the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK) exclusive, ex-Chinese rights to develop and commercialize BeiGene-290, a poly(ADP-ribose) polymerase (PARP) inhibitor in preclinical development for cancer. BeiGene will receive an undisclosed upfront payment and is eligible for up to EUR 170 million ($227.2 million) in milestones, plus royalties. BeiGene-290 is expected to enter the clinic next year. ...